Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

Annals of Oncology

Volumn 12, Issue 11, 2001, Pages 1527-1532

  Eiermann, W ^a   Paepke, S ^b   Appfelstaedt, J ^c   Llombart Cussac, A ^d   Eremin, J ^e   Vinholes, J ^f   Mauriac, L ^g   Ellis, M ^h   Lassus, M ⁱ   Chaudri Ross, H A ⁱ   Dugan, M ⁱ   Borgs, M ⁱ   Semiglazov, V ^j  

^a Frauenklinik Vom Roten Kreuz   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Instituto Valenciana de Oncologia   (Spain)

^e St George s Hospital   (United Kingdom)

^f Santa Casa de Porto Alegre   (Brazil)

^g INSTITUT BERGONIÉ   (France)

^h DUKE UNIVERSITY   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

more..

Author keywords

Breast conserving surgery; Letrozole; Postmenopausal; Preoperative; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; BREAST SURGERY; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOMAMMOGRAPHY; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PALPATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0035692576     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013128213451     Document Type: Article

References (29)

1. Consensus statement: Treatment of early-stage breast cancer
2. Should surgery remain the initial treatment of operable breast cancer?
3. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
4. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre
5. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124 month median follow-up
6. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
7. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: Five-year follow-up
8. Prospective randomized trial of tamoxifen vs. surgery in elderly patients with breast cancer
9. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial
10. Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone
11. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast carcinoma
12. Tamoxifen alone vs. surgery plus tamoxifen for breast cancer of the elderly: Meta analysis of long-term results of the GRETA and CRC trials
13. Letrozole is superior to tamoxifen as first-line hormonal treatment of post-menopausal women with locally advanced or metastatic breast cancer
14. Superior efficacy of letrozole (Femara®) vs. tamoxifen as first-line therapy for post-menopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
15. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
16. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2 positive, estrogen receptor positive primary breast cancer: Evidence from a phase 3 randomized trial
17. Tumor oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment
18. Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer
19. Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
20. From adjuvant to neoadjuvant chemotherapy in high risk breast cancer: The experience of the Milan Cancer Institute. Steiner Award Lecture 1992
21. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
22. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast
23. Neoadjuvant vs. adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast-conserving therapy: Preliminary results of a randomized study
24. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
25. Neoadjuvant chemotherapy in 126 operable breast cancers
26. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy